Genomic alteration analysis revealed that the high-risk group had higher prevalence of tumor suppressor genes RB1, FBXW7, and NFE2L2, consistent with the previous findings that the altered RB1 (50), FBXW7 (51), and NFE2L2 (52) were correlated with tumor progression and worse outcomes of BC patients. The gene discussed is NFE2L2; the disease is breast cancer.